drugset / Trial / NCT04041973

Study to Assess Efficacy of Artemether-lumefantrine Prophylaxis Against Forest Malaria in Cambodia (PAL_Cambodia)

NCT04041973 ↗

RandomizedParallel-groupSingle-blindPrevention

Summary

In the Greater Mekong Subregion (GMS) adults are at highest risk for malaria. The most relevant disease vectors bite during daytime and outdoors which makes forest work a high-risk activity for malaria. The absence of effective vector control strategies and limited periods of exposure during forest visits suggest that chemoprophylaxis could be an appropriate strategy to protect forest workers against malaria. The investigators propose the use of Artemether-lumefantrine (AL), a drug whose efficacy remains high in the GMS, unlike, for example DHA/piperaquine \[20\]. The proposed study will help to assess the efficacy and feasibility of prophylaxis to prevent malaria in forest workers, help to identify the optimal regimen, and predict its efficacy in reducing overall transmission. The proposed study is a critical step for future use of chemoprophylaxis to protect forest workers in the GMS against malaria. Funder: Wellcome Trust of Great Britain grant number 106698/Z/14/Z and 220211.

Timeline

Start
2020-03-11
Primary completion
2021-03-17
Completion
2021-03-17

Outcome

Met primary endpoint

paper 123 (17%, 15-20) of 714 in the multivitamin group (absolute risk difference 15%, 95% CI 12-18; p<0·0001). PMID 36174595 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Artemether-lumefantrine Unknown 20 mg —
Subject Artemether-lumefantrine Unknown 120 mg —

Indications